ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 502

Use, Usability and Feasibility of a Mapp for Patients with Rheumatoid Arthritis – First Results

Christina Kampling1, Gamal Chehab2, Hasan Acar1, Arnd Becker3, Matthias Schneider4 and Jutta G. Richter5, 1Policlinic of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 2Policlinic of Rheumatology, Heinrich-Heine-University, 40225 Duesseldorf, Germany, 3Ortenau Klinikum Offenburg-Gengenbach, Gengenbach, Gengenbach, Germany, 4Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, 5Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: eHealth ethics and rheumatoid arthritis (RA), Health Assessment Questionnaire

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Within the MiDEAR (Mobile medically supervised patient management in rheumatoid arthritis patients using DocuMed.rh and RheumaLive App) project patients (pts) with rheumatoid arthritis (RA) evaluate the usability of a mobile medical Application (mApp) with diary functions over nine months. The mApp includes two computerized patient-reported outcome questionnaires: the Hannover Functional Questionnaire (FFbH) and a modified RA disease activity index questionnaire (RADAI). In addition, it allows pts to document morning stiffness, pain (visual analogue scale), incapacity to work and medication. We studied pts’ use of this kind of mApp outside of out-pts clinics, their satisfaction and the reported benefits in real-life settings.

Methods:  Inclusion criteria were RA diagnosis, age of consent and German speaking. 268 consecutive RA out-pts (73.5% female) were screened, 157 (58.6%, 77.7% female) owned an App-able device. At baseline 60 out-pts consented to start the project. Pts downloaded the mApp on their own mobile device (either smartphone or TabletPC), documented their data voluntarily on not pre-specified intervals, and were followed on routine out-pts visits. During the out-pts visits pts evaluated the use, usability and feasibility of the mApp on paper-based questionnaires. Ethical approval and signed informed consents were obtained. The study is registered with the identifier NCT02565225 at clinicaltrials.gov.

Results: At baseline pts were predominantly female (78.3%), mean±SD age was 50.1±13.1 years (yrs), mean disease duration 10.5±9.1 yrs. 50% had a high education level. 90.0% already used Apps. 71.7% (n=43) remained in the project until the first follow-up. Reasons for discontinuation were fear of data theft (n=1), incompatible operating system (n=1), and other not App-related reasons (n=15). 97.7% (n=42) of the attending pts evaluated the mApp at first follow-up, n=39 had used the mApp at unspecific dates in between. Due to physical limitations (finger deformations) one patient reported problems to operate the mApp on a smartphone. Most pts (90.7%) rated mApp handling as easy. The average score of satisfaction with the mApp was 2.3±1.0 (Likert scale 1 (very satisfied) – 6 (very unsatisfied)) and the usefulness was 2.1±1.1 (Likert scale 1 (very useful) – 6 (not at all useful). Most pts (51.1%) stated that the mApp assisted them in an optimized self-monitoring of their disease. Better dealing with RA-related physical and medical needs due to App use was answered diversified with positive and negative responses.

Conclusion:  At first follow-up the mApp use was feasible in the majority of the pts. mApp users were satisfied with the mApp and assessed its utility as useful for self-monitoring their disease apart from out-pts visits. mApps – powerful tools at our fingertips – open great options for new management concepts. The ongoing project will deliver further data.


Disclosure: C. Kampling, None; G. Chehab, None; H. Acar, None; A. Becker, None; M. Schneider, None; J. G. Richter, None.

To cite this abstract in AMA style:

Kampling C, Chehab G, Acar H, Becker A, Schneider M, Richter JG. Use, Usability and Feasibility of a Mapp for Patients with Rheumatoid Arthritis – First Results [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/use-usability-and-feasibility-of-a-mapp-for-patients-with-rheumatoid-arthritis-first-results/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-usability-and-feasibility-of-a-mapp-for-patients-with-rheumatoid-arthritis-first-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology